


Applicants: Meir Shinitzky, et al.
Serial No.: 11/510,038
Filed : October 9, 2003
Page 2


REMARKS

In the September 22, 2008 Office Action, the Examiner required restriction to one of the following allegedly independent and distinct inventions:

- I. Claims 49-57 and 64-72 (in part) drawn to methods for the treatment of inflammation comprising administering a compound of formula I wherein the residue A is of the formula below, as defined in claim 54;




- II. Claims 49-54, 58-60, and 64-72 (in part) drawn to methods for the treatment of inflammation comprising administering a compound of formula I wherein the residue A is a phenyl, whose substitutions are defined in claim 54;
- III. Claims 49-54 and 61-72 (in part) drawn to methods for the treatment of inflammation comprising administering a compound of formula I wherein the residue A is of the formula below, as defined in claim 54;




- IV. Claims 135-149, 156-164, 186-197 and 204-212 (in part) drawn to a method of treating a T-cell mediated disease and a method of causing a shifting of T-cell cytokine response by

Applicants: Meir Shinitzky, et al.
Serial No.: 11/510,038
Filed : October 9, 2003
Page 3

administering a compound of formula Ia wherein the residue A is of the formula below, as defined in claim 142;



- V. Claims 135-142, 150-152, 156-164, 186-190, 198-200, and 204-212 (in part) drawn to a method of treating a T-cell mediated disease and a method of causing a shifting of T-cell cytokine response by administering a compound of formula Ia wherein the residue A is phenyl, whose substitutions are defined in claim 142;
- VI. Claims 135-142, 153-164, 186-190, and 201-212 (in part) drawn to a method of treating a T-cell mediated disease and a method of causing a shifting of T-cell cytokine response by administering a compound of formula Ia wherein the residue A is of the formula below, as defined in claim 142;



- VII. Claims 165-185 (in part) drawn to compounds of the general formula R1-O-CO-A wherein one of (i), (ii), (iii), or (iv), is true;
- VIII. Claims 165-185 (in part) drawn to compounds of the general formula R1-O-CO-A wherein (v) is true; and
- IX. Claims 165-185 (in part) drawn to compounds of the general

Applicants: Meir Shinitzky, et al.
Serial No.: 11/510,038
Filed : October 9, 2003
Page 4

formula R1-O-CO-A wherein (vi) is true.

With the election of any one of Groups I-IX, there is an additional requirement to elect a particular compound by providing the following:


- a) the name and structure of the instantly claimed compound;
- b) the location of the species (a) within the claims or (b) within the specification;
- c) the claims that read on the elected species; and
- d) a definition of the exact substitutions (e.g. R₁ is Hydrogen, X is Oxygen, etc...) .

If any one of Groups I-VI is elected, there is an additional requirement to elect a single disease or disorder to be treated.

Applicants' Reply

In response to the restriction requirement, applicants hereby elect Group VII.

In response to requirement for an election of a particular compound, applicants hereby elect α -amino- α -phenyl acetic acid octadec-(Z)-9-enyl ester as the compound species. The structure of the elected compound is:



Wherein R₁ is cis-9-octadecenyl, R₂ is phenyl, R₃ is a pair of electrons, R₄ and R₅ is each hydrogen.

Applicants: Meir Shinitzky, et al.
Serial No.: 11/510,038
Filed : October 9, 2003
Page 5

The elected species is located in claim 182, and claims that read on the elected species are 165(i), 166, 167, 168, 181, 182, 183, 184 and 185.

In addition, applicants respectfully request that the Examiner reconsider and withdraw the restriction of Group I. Under 37 C.F.R. §1.141 method of use claims of Group I should be examined along with the elected product claims. As required by Rule 141, the method of use claims recite compounds including those of the elected product claims. Accordingly, applicants hereby request pursuant to 37 C.F.R. §1.141(b) withdrawal of the restriction requirement of method of use claims 49-57 and 64-72 (in part), from the elected product claims.